Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS… Read more
Oncternal Therapeutics Inc (ONCT) - Total Assets
Latest total assets as of September 2024: $15.60 Million USD
Based on the latest financial reports, Oncternal Therapeutics Inc (ONCT) holds total assets worth $15.60 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Oncternal Therapeutics Inc - Total Assets Trend (1999–2023)
This chart illustrates how Oncternal Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Oncternal Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Oncternal Therapeutics Inc's total assets of $15.60 Million consist of 98.2% current assets and 1.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.2% |
| Accounts Receivable | $632.00K | 1.7% |
| Inventory | $1.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1999–2023)
This chart illustrates how Oncternal Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oncternal Therapeutics Inc's current assets represent 98.2% of total assets in 2023, an increase from 91.9% in 1999.
- Cash Position: Cash and equivalents constituted 18.2% of total assets in 2023, down from 91.9% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1999.
- Asset Diversification: The largest asset category is accounts receivable at 1.7% of total assets.
Oncternal Therapeutics Inc Competitors by Total Assets
Key competitors of Oncternal Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Oncternal Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Oncternal Therapeutics Inc generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Oncternal Therapeutics Inc is currently not profitable relative to its asset base.
Oncternal Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.39 | 8.25 | 2.83 |
| Quick Ratio | 2.39 | 8.28 | 2.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.99 Million | $ 37.34 Million | $ 13.45 Million |
Oncternal Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Oncternal Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.17 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -46.5% |
| Total Assets | $36.73 Million |
| Market Capitalization | $1.43 Million USD |
Valuation Analysis
Below Book Valuation: The market values Oncternal Therapeutics Inc's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Oncternal Therapeutics Inc's assets decreased by 46.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Oncternal Therapeutics Inc (1999–2023)
The table below shows the annual total assets of Oncternal Therapeutics Inc from 1999 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $36.73 Million | -46.50% |
| 2022-12-31 | $68.65 Million | -26.64% |
| 2021-12-31 | $93.58 Million | -21.23% |
| 2020-12-31 | $118.81 Million | +446.40% |
| 2019-12-31 | $21.74 Million | -30.58% |
| 2018-12-31 | $31.32 Million | -32.26% |
| 2017-12-31 | $46.24 Million | +88.70% |
| 2016-12-31 | $24.50 Million | -23.51% |
| 2015-12-31 | $32.03 Million | -36.76% |
| 2014-12-31 | $50.65 Million | +224.58% |
| 2013-12-31 | $15.61 Million | -72.99% |
| 2012-12-31 | $57.77 Million | -26.11% |
| 2011-12-31 | $78.18 Million | +21.69% |
| 2010-12-31 | $64.25 Million | +11.31% |
| 2009-12-31 | $57.72 Million | -46.61% |
| 2008-12-31 | $108.11 Million | -32.32% |
| 2007-12-31 | $159.73 Million | +23.58% |
| 2006-12-31 | $129.25 Million | +56.08% |
| 2005-12-31 | $82.81 Million | +13.31% |
| 2004-12-31 | $73.08 Million | +322.20% |
| 2003-12-31 | $17.31 Million | +72.58% |
| 2002-12-31 | $10.03 Million | -0.86% |
| 2001-12-31 | $10.12 Million | +216.06% |
| 2000-12-31 | $3.20 Million | +90.76% |
| 1999-12-31 | $1.68 Million | -- |